Author

Ting Wang

Observed name: T. Wang

Institution: Cancer Hospital of Huanxing Chaoyang District Beijing

Observed institution: Cancer Hospital of Huanxing Chaoyang District Beijing

ORCID: 0009-0004-1510-4133

Observed ORCID: 0009-0004-1510-4133

OpenAlex ID: A5024214887

Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al. · Clinical Cancer Research · 20

The retrospective study of single-agent capecitabine in the maintenance treatment of recurrent and metastatic breast cancer.

2010 · H. Huang, Z. Jiang, et al. · Journal of Clinical Oncology · 1

1291eP Pola-R-CHP regimen as first-line treatment for newly diagnosed high-risk diffuse large B-cell lymphoma (DLBCL) patients

2025 · J. Pi, X. He, et al. · Annals of Oncology

Supplementary Figure S2 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Supplementary Figure S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Supplementary Table S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Supplementary Methods S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Supplementary Figure S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Supplementary Table S2 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Data from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Supplementary Figure S3 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Data from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Supplementary Table S1 from Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

2024 · Yajin Chen, Chengyou Du, et al.

Works count: 13

Citation count: 21

H-index: 1

I10-index: 1